Is elimination of hepatitis C virus realistic by 2030: Eastern Europe

Isakov, Vasily; Цыркунов, В. М.; Nikityuk, D. B.

doi:10.1111/liv.14836

Cited by 6 publications

(2 citation statements)

References 16 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent survey of primary care professionals indicated that most HCV testing among existing migrant patients was done opportunistically rather than through systematic identification of high-risk patients, with only 17% of respondents stating that they offered universal opt-out HCV testing to newly registering migrant patients [ 51 ]. Specific barriers that migrants may face in accessing testing and subsequent linkage to care include language [ 52 ] (with a fifth of pregnant women screening positive for hepatitis B in England in 2014 having a less than basic level of English) [ 53 ], uncertainties around migrants’ entitlement to healthcare (which also exist among healthcare professionals) [ 51 ], and possible intersectional risk, particularly relating to IDU among migrants from Eastern Europe [ 54 , 55 ]. Furthermore, the lack of identifiable risk factors for some women may fail to identify some infected women, as was seen more than 20 years ago with selective antenatal screening for HIV in the UK [ 56 ], resulting in missed opportunities for postpartum treatment or follow-up of the HCV-exposed child.…”

Section: Discussionmentioning

confidence: 99%

Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling

Dema

Stander²,

Cortina‐Borja³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background The UK National Screening Committee currently recommends against antenatal screening for Hepatitis C virus (HCV) infection in England due to lack of HCV prevalence data and treatment licensed for use in pregnancy. We aimed to produce regional and national estimates of the number and proportion of livebirths to HCV seropositive women in England in 2013 and 2018. Methods A logistic regression model fitted in the Bayesian framework estimated probabilities of HCV seropositivity among 24,599 mothers delivering in the North Thames area of England in 2012 adjusted by maternal age and region of birth. These probabilities were applied to the underlying population structures of women delivering livebirths in England in 2013 and 2018 to estimate the number of livebirths to HCV seropositive women in these years nationally and by region. The Bayesian approach allowed the uncertainty associated with all estimates to be properly quantified. Results Nationally, the estimated number of livebirths to women seropositive for HCV for England was 464 (95% credible interval [CI] 300–692) in 2013 and 481 (95%CI 310–716) in 2018, or 70.0 (95%CI 45.0–104.1) per 100,000 and 76.9 (95%CI 49.5–114.4) per 100,000 in these years respectively. Regions with the highest estimated number of livebirths to HCV seropositive women in 2013 and 2018 included London with 118.5 and 124.4 and the South East with 67.0 and 74.0 per 100,000 livebirths. Conclusion Few previous studies have investigated HCV among pregnant women in England. These findings complement and supplement existing research by providing national and regional estimates for the number of livebirths to HCV seropositive women in England. Bayesian modelling allows future national and regional estimates to be produced and the associated uncertainty to be properly quantified.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling

Dema

Stander²,

Cortina‐Borja³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…About 71 million people worldwide are infected with hepatitis C [1]. The prevalence in Eastern European countries is 2-3% [2][3][4]. Patients with advanced liver disease or fibrosis should be treated promptly [5].…”

Section: Introductionmentioning

confidence: 99%

Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis

Khan,

Nazmin,

Ray

et al. 2024

J. Adv. Med. Med. Res.

View full text Add to dashboard Cite

Chronic hepatitis C with cirrhosis is treated with direct-acting antibiotics (DAAs). The aim of this study was to investigate the effect of direct-acting antibodies in the treatment of hepatitis C in cirrhosis. It also examines the proportion of drug-related problems, side effects, and mortality. The Cochrane Library and PubMed were thoroughly searched for the required literature. Fifteen articles were extracted for inclusion in this systematic review and meta-analysis. A total of 16 studies were thoroughly screened. The included studies provided a comprehensive picture of the effects of DAA therapy, spanning multiple study designs and sites Our analysis showed that good responses were observed with DAA regimens and that treatment discontinuation was low due to adverse events a stirring that. Few adverse events were reported, but all were mostly uncontrolled to prevent treatment discontinuation or death. In addition, meta-analytic studies on specific outcomes such as encephalopathy, ascites, hepatocellular carcinoma (HCC), adverse events, and death provided quantitative analysis about the safety of DAAs. Research also shows that DAAs have fewer side effects, deaths, and complications than other treatments.

show abstract

Chronic hepatitis C: Diagnosis and treatment made easy

Abu‐Freha

Jacob

Elhoashla

et al. 2022

European Journal of General Practice

View full text Add to dashboard Cite

Background Hepatitis C Virus (HCV) is a common cause of chronic liver disease and its ensuing complications. In the last years, there has been a revolution of the treatment for patients with HCV regarding efficacy, simplicity, safety and duration of treatment. The role of the family physician is vital in all steps of care: screening, diagnosis, linkage to treatment, treatment and follow-up. Objectives This review aims to summarise the family physician and the important updated recommendations for diagnosis and treatment of patients with chronic HCV. Methods The updated recommendations were reviewed and summarised in a short and simple review. Results Patients with any risk factor for HCV should first be screened for HCV antibodies. In the case of positive antibodies, reflex testing for RNA polymerase chain reaction (PCR) should be done without waiting for genotype. For patients with positive PCR, fibrosis assessment should be conducted using laboratory panels (Fibrosis-4 index (FIB-4) or aspartate aminotransferase to platelet ratio index (APRI)); if advanced fibrosis is suspected, additional non-invasive fibrosis assessment is needed, such as fibrotest or liver elastography. Naïve non-cirrhotic or compensated cirrhosis (Child-Pugh-Score A) could be treated with pangenotypic drugs, Glecaprevir/pibrentasvir (Maviret) for eight weeks, or Sofosbuvir/velpatasvir (Epclusa) for 12 weeks. Conclusion Patients without advanced fibrosis and comorbidities can be treated by the educated family physician. However, patients with comorbidities, cirrhosis or coinfection (HIV, Hepatitis B Virus (HBV)) should be referred to the liver clinic. In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce.

show abstract

Is elimination of hepatitis C virus realistic by 2030: Eastern Europe

Cited by 6 publications

References 16 publications

Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling

Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling

Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis

Chronic hepatitis C: Diagnosis and treatment made easy

Contact Info

Product

Resources

About